Close Menu
Home » CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients

CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients

Jan 27, 2020
|
staff reporter

NEW YORK – The Centers for Medicare & Medicaid Services on Monday finalized the criteria under which it will grant national coverage to next-generation sequencing tests for assessing inherited cancer risk.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

And Out

A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.

Quick Generation

Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.

Phages With More

Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.

PNAS Papers Examine Prostate Cancer Splicing, Arabidopsis Methylation, X Chromosome Dosage Effects

In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.

What's Popular?

In Reimbursement News

  1. CGS Administrators Aligns LCD for DermTech Pigmented Lesion Assay With Palmetto

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.